

SUBJECT: RSV Immunization Programs – Fall/Winter 2026/27
Date: September 30, 2026
Pages: 2 (plus attachment)
To: Primary Care Providers, Hospitals, Long-Term Care Homes, Retirement Homes
From: Dr. Matthew Tenenbaum, Associate Medical Officer of Health

- Arexvy, Abrysvo and Beyfortus will be available to order from Wellington-Dufferin-Guelph (WDG) Public Health this fall.
- All adults 75 years of age and older eligible for Arexvy/Abrysvo.
- Beyfortus is no longer preferred over Abrysvo for infant protection. Abrysvo can now be administered as early as 28 weeks gestational age (GA).

Provincial publicly funded respiratory syncytial virus (RSV) programs will continue in fall/winter 2026/27. Please see below for updates and other key information.

Older Adult RSV Program

The vaccines **Arexvy** and/or **Abrysvo** will be available to the following groups:

- All adults **75 and older**.
- Adults **60 and older** who are:
 - Residing in a long-term care home, retirement home or elder care lodge.
 - Receiving alternate level of care (ALC) in hospital.
 - On home oxygen or requiring chronic oxygen therapy, regardless of residence (**NEW for 2026/27**).
 - Patients with glomerulonephritis (GN) who are moderately to severely immunocompromised.
 - Receiving hemodialysis or peritoneal dialysis.
 - Recipients of solid organ or hematopoietic stem cell transplants within the past two years or with ongoing immunosuppression.
 - Experiencing homelessness.
 - Individuals who identify as First Nations, Inuit or Métis.

Individuals who previously received an RSV vaccine do not need to be re-immunized.

For more information, please refer to the [Ministry's Older Adult High-Risk Respiratory Syncytial Virus \(RSV\) Vaccine Program Fact Sheet](#).

Infant & High-Risk Child RSV Program

The monoclonal antibody product **Beyfortus (nirsevimab)** will be available for the following eligible groups:

- Infants born on or after April 1 and <8 months old at the time of administration
- Children **up to 24 months old** with any of the following:
 - Chronic lung disease of prematurity, including bronchopulmonary dysplasia
 - Hemodynamically significant congenital heart disease
 - Severe immunodeficiency
 - Down syndrome
 - Cystic fibrosis with recurrent pulmonary exacerbations, pulmonary deterioration, and/or severe growth delay
 - Neuromuscular disease or severe congenital airway anomalies impairing clearing of respiratory secretion

WDG Public Health Physicians Advisory
RSV Immunization Programs – Fall/Winter 2026/27
September 30, 2026
Page 2 of 2

Dosing remains age and weight-based:

Infants (1 st RSV Season)		Children (2 nd RSV Season)
< 5 kg	≥ 5 kg	
50 mg (0.5 mL)	100 mg (1 mL)	200 mg (2 x 1 mL)

Children who received Beyfortus last season should receive it again this season, if they are still eligible. Each dose only provides protection for a single RSV season.

The vaccine **Abrysvo** will be available for **pregnant individuals between 28-36 weeks GA** who will deliver during the RSV season (November through March). The National Advisory Committee on Immunization (NACI) now recommends that Abrysvo can be administered as early as 28 weeks GA, though this remains off-label. Individuals who received Abrysvo during a previous pregnancy are not recommended to receive it during a subsequent pregnancy; consider Beyfortus in these instances.¹

NACI no longer recommends Beyfortus over Abrysvo as a means of protecting infants from RSV; either is considered adequate.¹ Administration of both products is not recommended unless:

- Infant was born <14 days after Abrysvo was administered.
- Infant is premature (<37 weeks GA).
- Infant has any risk factor listed above.

For more information, please refer to the – [Ministry's Infant and High-risk Children Respiratory Syncytial Virus \(RSV\) Prevention Program Fact Sheet](#).

Ordering

Arexvy and Abrysvo are available to order now. Beyfortus will be available to order on October 1, 2026.

WDG Public Health will work directly with long-term care homes and retirement homes to coordinate vaccine distribution. Community-based healthcare providers should fax a completed **RSV and RSV Prophylaxis Order Form** (attached) to **519-823-4903**.

Arexvy, Abrysvo and Beyfortus can all be co-administered with flu, COVID-19 and other routine vaccines.

References:

1. Government of Canada. Summary of NACI statement of April 10, 2026: Updated guidance to protect infants and children from respiratory syncytial virus (RSV) disease: Use of monoclonal antibodies (nirsevimab and clesrovimab) and the RSVpreF vaccine, accessed September 24, 2026. Available at: <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-infants-children-respiratory-syncytial-virus-use-monoclonal-antibodies-nirsevimab-clesrovimab-rsvpref-vaccine.html>

For more information, please contact:

Name/Title: April Pollington, Manager, Clinical Services – Community Health Division
Email: April.Pollington@wdgpublichealth.ca
Website: <https://wdgpublichealth.ca/>